Immunotherapy significantly improved survival rates in patients with head and neck squamous cancer

head and neck cancer includes tumors such as oral, pharynx, throat, nose and salivary gland tumors, and 90 per cent of all head and neck cancer patients are squamous cell carcinomas. Early head and neck squamous cancer can be achieved by surgery or radiotherapy to cure some patients, but 70% to 80% of patients with head and neck cancer are diagnosed in the local late stage or metastatic stage, the need for drug treatment to join. China Clinical Oncology Society head and neck tumor professional
association director
, Shanghai Oriental Hospital, deputy director of the Department of Oncology Professor Guo Wei introduced, China's annual newly diagnosed head and neck cancer patients more than 137,000, and advanced head and neck cancer due to lack of chemotherapy other treatment options, treatment is difficult.
The official website of the National Drug Administration (NMPA) recently revealed that Merca East PD-1 inhibitor Pabli pearl monotherapy (Corida) monodramine has been approved for first-line treatment through fully validated testing to assess patients with metastatic or non-removable refraction head and neck squamous cell carcinoma (HNSCC) of PD-L1 expression positive (CPS≥20). This approval is based on the total lifetime data from the keyNOTE-048 study of a large-scale Phase III clinical trial worldwide, which aims to assess the efficacy and safety of patients with Paboliju single-drug or combined chemotherapy first-line treatment with relapsed or metastatic head and neck squamous cell carcinoma.
Professor Guo Wei, the KEYNOTE-048 study included a total of 882 patients with relapsed or metastatic head and neck squamous cancer, including oral, oral and pharynx, pharynx and throat cancer, randomly assigned to the Paboli Pearl Single Anti-Single Drug Group, The Pabli Pearl Single Anti-Combination Chemotherapy Group and the Targeted Joint Chemotherapy Group at 1:1:1. According to the latest data published in the 2020 European EsMO study, Paboliju monoantigen-targeted combination chemotherapy survives for 4 years in patients with PD-L1 positive (CPS≥20) The rate was almost tripled, from 8% to 21.6%, and the efficacy was significantly better than that of the standard scheme, the total survival time of the patient was extended from 10.8 months to 14.9 months, and the risk of disease death was reduced by 39%, the rate of adverse reactions decreased significantly, and the patient's tolerance was better. In patients with tumor remission, the medium duration of remission was up to 23.4 months.
Professor Guo Wei said: "At present, squamous cancer is more suitable for immunotherapy and there are many studies on head and neck squamous cancer that have shown a closely related to immune escape, and if immunotherapy can reverse the immune escape of tumors will be a great success in head and neck squamous cancer." THE KEYNOTE-048 study is a cross-era study of head and neck squamous cancer, which establishes the classic position of Pabli Pearl mono-anti-first-line treatment for recurrence metastatic head and neck squamous cancer. This year's ESMO long-term data update is even more special. Over time, the long-term survival benefits of Paboliju monoantigen in a certain group of patients have even reached near-cure effects, which has been rare in previous treatments. "